Neon Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Neon Therapeutics's estimated annual revenue is currently $14.1M per year.
- Neon Therapeutics received $36.0M in venture funding in December 2017.
- Neon Therapeutics's estimated revenue per employee is $641,136
- Neon Therapeutics's total funding is $161M.
Employee Data
- Neon Therapeutics has 22 Employees.
- Neon Therapeutics grew their employee count by -8% last year.
Neon Therapeutics's People
| Name | Title | Email/Phone |
|---|
Neon Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Neon Therapeutics?
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. For more information, please visit www.neontherapeutics.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$161M
Total Funding
22
Number of Employees
$14.1M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neon Therapeutics News
Global Precision Medicine Market Information, Figures and Analytical Insights By 2028 | Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG,...
Moderna Therapeutics; F. Hoffmann-La Roche Ltd; AstraZeneca plc; Agenus; OSE Immunotherapeutics; Advaxis; Medigene; Neon Therapeutics...
Thinly traded nano cap Neon Therapeutics (NASDAQ:NTGN) is up 14% premarket on average volume in response to a just-published paper in ...
Neon Therapeutics Inc (NTGN) stock has fallen -66.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong ...
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens.
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 22 | -41% | N/A |
#2 | $3.1M | 22 | N/A | N/A |
#3 | $2.8M | 22 | 0% | N/A |
#4 | $2.2M | 22 | -8% | N/A |
#5 | $2.2M | 22 | 0% | N/A |
Neon Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-10-02 | $55.0M | A | Third Rock Ventures | Article |
| 2017-01-06 | $70.0M | B | Partner Fund Management | Article |
| 2017-12-06 | $36.0M | B | Article |